Cartwright’s research interests focus on the discovery and engineering of therapeutic and diagnostic antibodies. Before joining the Wyss, he worked in the pharmaceutical industry for three years using Phage Display for the discovery, design, and production of therapeutic monoclonal antibodies for cancer treatment. Prior research includes the study of age-related changes in preadipocytes and work in the area of neuronal differentiation and survival with a focus on neurotrophins. Cartwright has a patent stemming from his work on the isolation of a novel toxin from Borrelia Burgdorferi, the causative agent of Lyme disease. He received his B.Sc in Neurobiology from McGill University and his Ph.D. in Pharmacology and Experimental Therapeutics from Boston University.
Mark J. Cartwright, Ph.D.
Senior Scientist II